14 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.
The next term ends in Jun 2029. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Jun 2029
Next term end
6
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2031 · High confidence
Also notable
Ends Jun 2029 · High confidence
Also notable
Ends May 2037 · Medium confidence
Methods for Increasing Intracellular Activity of HSP70
US 9,662,375
The most cited patent in this portfolio, cited by 37 later US patents, top 10% of utility patents granted in 2017 in our data. Protection runs to 2031.
Use of HSP70 as a Regulator of Enzymatic Activity
US 11,304,941
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2029. A terminal disclaimer caps this term to an earlier patent's.
Arimoclomol for Treating Glucocerebrosidase Associated Disorders
US 11,253,505
A family of 5 related applications built on the 2022 grant. Protection runs to 2037.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 25, 2027The maintenance fee for Processes for Preparing Arimoclomol Citrate and Intermediates Thereof (US 11,707,456) comes due Jan 25, 2027. Unpaid by Jul 26, 2027, it lapses early.
- 2 fees due Jul 14 to 28, 2027 · next Jul 14
- 2 fees due Sep 22 to 26, 2027 · next Sep 22
Recent changes
- Oct 9Assignment recorded on 1 record: Kempharm Denmark A/S to Zevra Denmark A/S Recorded Oct 9, 2026, executed Jul 5, 2023. Conveyance as recorded: Change of Name. A recorded assignment is a filed document, not a statement of current ownership. Reel 76671, frame 341.
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Use of HSP70 as a Regulator of Enzymatic Activity | 7 in force | to Oct 2029 |
| Arimoclomol Formulation | 2 in force | to Dec 2035 |
| Methods for Increasing Intracellular Activity of HSP70 | 2 in force | to Nov 2031 |
| Processes for Preparing Arimoclomol Citrate and Intermediates Thereof | 1 in force | to Nov 2041 |
| Arimoclomol for Treating Glucocerebrosidase Associated Disorders | 1 in force | to May 2037 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,884,058 | Use of HSP70 as a Regulator of Enzymatic Activity In force · High confidence | In force | High confidence | |
| US 11,045,460 | Use of HSP70 as a Regulator of Enzymatic Activity In force · High confidence | In force | High confidence | |
| US 11,304,941 | Use of HSP70 as a Regulator of Enzymatic Activity In force · High confidence | In force | High confidence | |
| US 11,938,125 | Use of HSP70 as a Regulator of Enzymatic Activity In force · High confidence | In force | High confidence | |
| US 8,540,985 | Use of HSP70 as a Regulator of Enzymatic Activity In force · High confidence | In force | High confidence | |
| US 9,289,472 | Use of HSP70 as a Regulator of Enzymatic Activity In force · High confidence | In force | High confidence | |
| US 10,543,204 | Use of HSP70 as a Regulator of Enzymatic Activity In force · High confidence | In force | High confidence | |
| US 9,662,375 | Methods for Increasing Intracellular Activity of HSP70 In force · High confidence | In force | High confidence | |
| US 10,532,085 | Methods for Increasing Intracellular Activity of HSP70 In force · Medium confidence | In force | Medium confidence | |
| US 11,229,633 | Arimoclomol Formulation In force · High confidence | In force | High confidence |
Also on record, not counted in the 14: 1 patent in force now held by others · 9 applications pending · 4 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.